Human Molecular Genetics Advance Access originally published online on November 30, 2005
Human Molecular Genetics 2006 15(1):105-111; doi:10.1093/hmg/ddi432
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Prevention of oculopharyngeal muscular dystrophy-associated aggregation of nuclear poly(A)-binding protein with a single-domain intracellular antibody
1Department of Molecular and Cellular Biology, University of Utrecht, Padualaan 8, 3584 CH Utrecht, The Netherlands, 2Leiden University Medical Center, Center for Human and Clinical Genetics, Leiden, The Netherlands and 3Ablynx nv, Ghent, Belgium
* To whom correspondence should be addressed. Tel: +31 302535421; Fax: +31 302513655; Email: pverheesen{at}hotmail.com
Received September 12, 2005; Accepted November 18, 2005
Oculopharyngeal muscular dystrophy (OPMD) belongs to the group of protein aggregation disorders and is caused by extensions of the N-terminal polyalanine stretch of the nuclear poly(A)-binding protein 1 (PABPN1). The presence of PABPN1-containing intranuclear aggregates in skeletal muscle is unique for OPMD and is also observed in transgenic mouse and cell models for OPMD. These models consistently support a direct role for the protein aggregation in OPMD pathogenesis. We have isolated and characterized a diverse panel of single-domain antibody reagents (VHH), recognizing different epitopes in PABPN1. The antibody reagents specifically detect endogenous PABPN1 in cell lysates on western blot and label PABPN1 in cultured cells and muscle sections. When expressed intracellularly as intrabodies in a cellular model for OPMD, aggregation of PABPN1 was prevented in a dose-dependent manner. More importantly yet, these intrabodies could also reduce the presence of already existing aggregates. Given the domain specificity of VHH-mediated aggregation interference, this approach at least allows the definition of the nucleation kernel in aggregation-prone proteins, thus facilitating etiological insight into this and other protein aggregation disorders, and ultimately, it may well provide useful therapeutic agents.
These authors contributed equally to this work.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Chartier, V. Raz, E. Sterrenburg, C. T. Verrips, S. M. van der Maarel, and M. Simonelig Prevention of oculopharyngeal muscular dystrophy by muscular expression of Llama single-chain intrabodies in vivo Hum. Mol. Genet., May 15, 2009; 18(10): 1849 - 1859. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Forsman, E. Beirnaert, M. M. I. Aasa-Chapman, B. Hoorelbeke, K. Hijazi, W. Koh, V. Tack, A. Szynol, C. Kelly, A. McKnight, et al. Llama Antibody Fragments with Cross-Subtype Human Immunodeficiency Virus Type 1 (HIV-1)-Neutralizing Properties and High Affinity for HIV-1 gp120 J. Virol., December 15, 2008; 82(24): 12069 - 12081. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Nagel, M. Scherr, A. Kel, K. Hornischer, G. E. Crawford, M. Kaufmann, C. Meyer, H. G. Drexler, and R. A.F. MacLeod Activation of TLX3 and NKX2-5 in t(5;14)(q35;q32) T-Cell Acute Lymphoblastic Leukemia by Remote 3'-BCL11B Enhancers and Coregulation by PU.1 and HMGA1 Cancer Res., February 15, 2007; 67(4): 1461 - 1471. [Abstract] [Full Text] [PDF]
|
|